Drug–drug interactions between gender‐affirming hormone therapy and antiretrovirals for treatment/prevention of HIV

Documenti analoghi

• A case report highlighting drug–drug interactions between 3 life‐saving treatments: Feminizing hormones, antiretrovirals and antituberculosis drugs
  di: Tara Suchak, et al.
  Pubblicazione: (2024)
• Assessing ChatGPT's capability in understanding and reporting antiretroviral therapy drug–drug interaction effects: Quantitative and qualitative results from the ACCURATE‐DDI study
  di: E. Ready, et al.
  Pubblicazione: (2025)
• No observed bidirectional effect between tenofovir diphosphate concentrations and gender‐affirming hormone concentrations among transgender persons switching from tenofovir disoproxil fumarate/emtricitabine to tenofovir alafenamide/emtricitabine for HIV pre‐exposure prophylaxis
  di: Nimish Patel, et al.
  Pubblicazione: (2024)
• The case of dolutegravir plus darunavir antiretroviral regimens: Is it always useful to double the drug doses?
  Pubblicazione: (2024)
• 2024 updates to the Québec antiretroviral therapeutic drug monitoring guidelines: Key changes over 10 years
  Pubblicazione: (2024)